Ibrance

Chemical Namepalbociclib
Dosage FormCapsule (oral; 75 mg, 100 mg, 125 mg)
Drug ClassKinase inhibitors
SystemFemale reproductive
CompanyPfizer Inc.
Approval Year2015

Indication

  • For the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.
Last updated on 1/12/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Ibrance (palbociclib) Prescribing Information 2019Pfizer labs, NY, NY
Document TitleYearSource
NCCN guidelines updates: Breast cancer.2018Journal of the National Comprehensive Cancer Network
Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology guideline.2016Journal of Clinical Oncology